Sanofi (SNY) and Pfizer (PFE) Face Competition from German Bidder in Struggle for Medivation (MDVN) - Source
Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.
Medivation's (Nasdaq: MDVN) competitive sale process is nearing its final stages, according to a source claiming to have knowledge of the matter. So far the San Francisco-based maker of XTANDI has received an offer from Pfizer (NYSE: PFE) and an improved offer from Sanofi (NYSE: SNY). The source also stated that a German drug company has entered the fray and plans to make a bid ahead of an upcoming deadline. The name of third bidder wasn't made known at this time.
The status of potential bids from Gilead (Nasdaq: GILD) and Celgene (Nasdaq: CELG), two companies mentioned as interested parties in previous media reports, wasn't discussed. Tomorrow is the deadline to submit an indication of interest.
Shares of Medivation last traded up 0.4% to $64.25.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Third-Party Said Interested in PrivateBancorp (PVTB) as CIBC (CM) Deal is Delayed
- AES emerges as bidder for TerraForm Power (TERP) - SparkSpread
- Sibanye Gold (SBGL) to Acquire Stillwater Mining Company (SWC) in $2.2B Deal
Create E-mail Alert Related CategoriesHot M&A, Mergers and Acquisitions, Rumors
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!